Abbott Laboratories (abt)
ABT — Company Overview
Abbott Laboratories (ABT) is a large-cap company in the Healthcare sector, operating in Medical Devices.
| Ticker | ABT |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NYQ |
| Market cap | $188.05B |
| Last price | $107.96 |
| Size category | Large Cap |
ABT — Business Description
Abbott Laboratories (ABT) operates in Medical Devices within the broader Healthcare market. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vacc…
Official website: https://www.abbott.com.
ABT — Investment Thesis
The investment thesis for Abbott Laboratories (ABT) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 13.0% year-over-year (public data).
- Trailing P/E of 34.27× sits in a moderate band relative to high-growth peers.
- Forward P/E (17.81×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.4% adds an income component to total return.
- Equity market capitalization is approximately $188.05B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
ABT — Financial Health
Financial health for Abbott Laboratories (ABT) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin near 11.6% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $7.21B supports balance-sheet flexibility.
| Trailing P/E | 34.27× |
| Forward P/E | 17.81× |
| Price / Sales | 4.04× |
| Price / Book | 3.66× |
| Gross margin | 56.8% |
| Operating margin | 14.7% |
| Profit margin | 11.6% |
| Return on equity | 10.6% |
| Debt / Equity | 63.21 |
| Free cash flow | $7.21B |
ABT — Growth Outlook
Growth outlook for Abbott Laboratories (ABT) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 13.0% indicates strong top-line momentum.
- Earnings declined -47.5% year-over-year — margin or volume pressure may be in play.
- Price is 21.5% below the 52-week high.
ABT — Competitive Position
Abbott Laboratories (ABT) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $188.05B places ABT among large-cap peers.
- Gross margin near 56.8% may reflect pricing power or favorable mix.
ABT — Strengths
Strengths for Abbott Laboratories (ABT) inferred from public financial metrics:
- Revenue growth of 13.0% year-over-year.
- Gross margin of 56.8% supports competitive unit economics.
- Positive free cash flow ($7.21B).
- Dividend yield of 2.4% for income-oriented holders.
- Moderate leverage (debt/equity 63.21).
- Large Cap scale ($188.05B) may provide distribution and funding advantages.
ABT — Weaknesses
Weaknesses and pressure points for Abbott Laboratories (ABT) based on available data:
- Earnings decline of -47.5% year-over-year.
ABT — Opportunities
- Sustained revenue growth (13.0%) could support multiple expansion if margins hold.
- Dividend yield of 2.4% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
ABT — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
ABT — Summary
Abbott Laboratories (ABT) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $107.96 with market cap $188.05B. Trailing P/E 34.27×. Revenue grew 13.0% year-over-year per public data. Notable strengths include revenue growth of 13.0% year-over-year. Key watch items include earnings decline of -47.5% year-over-year. Detailed estimates, ownership, and news for Abbott Laboratories remain locked in Vest Terminal for subscribers.
Abbott Laboratories FAQ
What does Abbott Laboratories (ABT) do?
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers…
What is ABT's P/E ratio?
Abbott Laboratories has a trailing P/E of 34.27× based on publicly available market data.
Does ABT pay a dividend?
Indicated dividend yield: 2.4%. Confirm ex-dates and payout history in Vest Terminal.
What sector is ABT in?
Abbott Laboratories is classified in Healthcare (Medical Devices) on NYQ.
What is ABT's market capitalization?
Approximate market cap: $188.05B.
What are the main risks for ABT?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of ABT?
Potential positives include revenue growth of 13.0% year-over-year, gross margin of 56.8% supports competitive unit economics.
Where can I get analyst estimates for ABT?
Consensus estimates, price targets, and detailed analyst data for Abbott Laboratories are available to Professional subscribers in Vest Terminal — not on this public summary page.